Stocktoria

Ceribell, Inc. CBLL

Nasdaq · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2024-10-11 · LEI

Ceribell, Inc. financials (annual)

Revenue
$45.2M $65.4M $89.1M 202320242025
Net income
-$29.5M -$40.5M -$53.4M 202320242025
Free cash flow
-$30.1M -$36.4M -$41.6M 202320242025

Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023
Revenue$89.1M$65.4M$45.2M
Gross profit$78.3M$56.8M$38.2M
R&D expense$19.1M$13.6M$9.0M
Operating income-$58.4M-$39.7M-$30.0M
Income tax$0$0$11,000
Net income-$53.4M-$40.5M-$29.5M
EPS (diluted)$-1.46$-3.39$-5.56
Operating cash flow-$40.8M-$35.0M-$29.2M
Free cash flow-$41.6M-$36.4M-$30.1M
Cash & equivalents$40.5M$194.4M$34.5M
Inventory$7.3M$6.9M$5.9M
Total assets$195.8M$225.4M$58.9M
Total liabilities$40.5M$34.2M$23.8M
Shareholders' equity$155.3M$191.2M-$112.3M

Growth · year-over-year · Revenue CAGR 40.3%

MetricFY2025FY2024FY2023
Revenue growth+36.1%+44.7%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.